

ONS/ASCO Guideline on the Management of Antineoplastic Extravasation.

Title: ONS/ASCO Guideline on the Management of Antineoplastic Extravasation.

Publication year: 2025

Journal: Clinical journal of oncology nursing

Authors: Tanya Thomas.

Society: American Society of Clinical Oncology

Origin country: United States

Target countries: United States

DOI: 10.1188/25.CJON.384-399

PMID: 40986763

Source: <https://pubmed.ncbi.nlm.nih.gov/40986763/>

Clin J Oncol Nurs Clin J Oncol Nurs 4735 clinjon 9705336 Clinical Journal of Oncology Nursing 1092-1095 1538-067X Oncology Nursing Society PMC12463152 PMC12463152.1 12463152 12463152 40986763 10.1188/25.CJON.384-399 cjon-295-384 1 Articles ONS/ASCO Guideline on the Management of Antineoplastic Extravasation Thomas Tanya DNP, APRN, AGCNS-BC™, OCN® Clark Caroline MSN, APRN, AGCNS-BC™, OCN®, EBP-C Backler Chelsea MSN, APRN, AGCNS-BC™, AOCNS®, VA-BC™ Bohlke Kari ScD Centofanti Deena MS, RN, AOCN® Jotwani Aparna C. MD Cope Diane G. PhD, APRN, BC, AOCNP® Dalton Kerri A. DNP, RN, AOCNS® Gochett Celestine G. PhD, ACNS-BC®, AOCNS® Henney Victoria BSN, RN, BMTCN®, OCN® King Gwen BSN, RN, OCN® Moore Donald C. PharmD, BCPS®, BCOP®, DPLA, FCCP, FASHP McManus Hannah Dzimitrowicz MD Anderson Holly M. BSN, RN Moriarty Kerri A. MLS Gibbs Karen DiValerio PhD, MSN/MPH, RN, CPN® Morgan Rebecca L. PhD, MPH Tanya Thomas, DNP, APRN, AGCNS-BC™, OCN®, is a clinical nurse specialist at UVA Health in Charlottesville, VA; Caroline Clark, MSN, APRN, AGCNS-BC™, OCN®, EBP-C, is the director of guidelines and quality, and Chelsea Backler, MSN, APRN, AGCNS-BC™, AOCNS®, VA-BC™, is an oncology clinical specialist, both at the Oncology Nursing Society in Pittsburgh, PA; Kari Bohlke, ScD, is a senior guideline specialist at the American Society of Clinical Oncology in Alexandria, VA; Deena Centofanti, MS, RN, AOCN®, is a clinical nurse specialist at Rutgers Cancer Institute in New Brunswick, NJ; Aparna C. Jotwani, MD, is an assistant professor in the Department of Medicine in the Section of Hematology and Oncology at Baylor College of Medicine in Houston, TX; Diane G. Cope, PhD, APRN, BC, AOCNP®, is an oncology nurse practitioner at Florida Cancer Specialists and Research Institute in Fort Myers; Kerri A. Dalton, DNP, RN, AOCNS®, is a clinical nurse specialist and the nursing program manager for evidence-based practice in the Nursing Research and Evidence-Based Practice Department at Duke University Health System in Durham, NC; Celestine G. Gochett, PhD, ACNS-BC®, AOCNS®, is an oncology clinical nurse specialist at Northside Hospital Cancer Institute in Atlanta, GA; Victoria Henney, BSN, RN, BMTCN®, OCN®, is a nurse at Karmanos Cancer Institute in Detroit, MI; Gwen King, BSN, RN, OCN®, is an associate nurse manager at the University of Colorado Hospital in Aurora; Donald C. Moore, PharmD, BCPS®, BCOP®, DPLA, FCCP, FASHP, is a clinical oncology pharmacy manager at Atrium Health Levine Cancer Institute in Charlotte, NC; Hannah Dzimitrowicz McManus, MD, is an assistant professor in the School of Medicine in the Department of Medicine, Medical Oncology, at Duke University and a medical oncologist in the Center for Prostate and Urologic Cancers at the Duke Cancer Institute, both in Durham, NC; Holly M. Anderson, BSN, RN, is the former president and executive director of the Breast Cancer Coalition in Rochester, NY; Kerri A. Moriarty, MLS, is a research specialist at the Oncology Nursing Society; Karen DiValerio Gibbs, PhD, MSN/MPH, RN, CPN®, is an assistant professor in the Department of Undergraduate Studies in the Cizik School of Nursing at the University of Texas Health Science Center at Houston; and Rebecca L. Morgan, PhD, MPH, is an adjunct assistant professor in the Department of Population and Quantitative Health Sciences in the School of Medicine at Case Western Reserve University and the executive director of the Evidence Foundation, both in Cleveland, OH, and an assistant professor in the Department of Health Research Methods, Evidence, and Impact in the Faculty of Health Sciences

at McMaster University in Hamilton, Ontario, Canada Thomas can be reached at tanya.thomas.onc.cns@outlook.com , with copy to CJONEditor@ons.org . The authors gratefully acknowledge Erica Fischer-Carlidge, DNP, CNS, AOCNS ® , EBP-C; Christine Gegeckas, RPh, BCOP ® , FFSHP; Ruth Van Gerpen, MS, RN, APRN-CNS, AOCNS ® , PGMT-BC ™ ; Elizabeth Shaw, CNP; Latha Subramanian, MD; Britt Meyer, PhD, RN, CRNI ® , VA-BC™, NEA-BC ® ; and the American Society of Clinical Oncology Evidence-Based Medicine Committee for their thoughtful reviews and insightful comments on this guideline.

10 2025 01 10 2025 29 5 497527 384 399 01 5 2025 06 6 2025 01 10 2026 05 03 2026 05 03 2026
Copyright 2025 by the Oncology Nursing Society 2025 Single-user license only. ONS reserves all rights. For permission to post online, reprint, adapt, or reuse, please email pubpermissions@ons.org . PURPOSE Extravasation is an uncommon but high-risk adverse event that occurs when an agent with the potential to cause tissue damage leaks out of the intended administration space into the surrounding area. This guideline presents evidence-based side effect management recommendations to support interprofessional teams in decision-making to minimize severity or progression of extravasation injury from antineoplastic treatment in individuals with cancer.

The Oncology Nursing Society and the American Society of Clinical Oncology appointed healthcare professional and patient representative members to a panel for guideline development focused on antineoplastic vesicants and irritants with vesicant properties. The panel applied GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology and followed the National Academies of Sciences, Engineering, and Medicine criteria for trustworthy guidelines. A systematic review of studies examining outcomes of antineoplastic agent extravasation in adults informed the guideline. The panel assessed the certainty of the evidence using the GRADE approach.

The panel agreed on recommendations related to the use of antidotes for antineoplastic vesicants and irritants with vesicant properties, thermal compress application and duration, and early surgical referral or escalation to specialty care for central venous access device extravasation.

This guideline summarizes evidence-based interventions for the management of extravasation of antineoplastic vesicants or irritants with vesicant properties to guide clinical care.